Prostate Cancer — BAY88-8223, Dose Finding Study in Patients With HRPC
Citation(s)
A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin® for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases